Stomach Adenocarcinoma Clinical Trial
Official title:
The Establishment of General Tissue Response Classification System After Chemotherapy According to Gastric Cancer Patients With Neoadjuvant Chemotherapy
This research intend to collect the information of gastric cancer patients who received preoperative neoadjuvant chemotherapy and radical gastric ectomy at Department of Gastrointestinal Surgery, West China Hospital, Sichuan University. Base on The degree of edema, intraoperative effusion, fibrosis of connecting tissues, the investigators aim to constitute the core parameters of the tissue response grading system following neoadjuvant chemotherapy, and explore the mutual effect among the tissue response grading system, tumor regression response and long-term survival outcome of tumor patients.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2020 |
Est. primary completion date | December 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. The diagnosis of gastric cancer was clear,Patients with definitely clinical evidence of locally advanced disease (cT3 / 4?N-/+?M0). 2. Preoperative chemotherapy has been administered,and intended to receive surgical resection. 3. Age:less than or equal to 75 years old and more than 18 years old; 4. Without any other malignant tumor, without any serious concomitant disease. 5. Eastern Cooperative Oncology Group (ECOG) physical status score <2, America Society of Anesthesiologist (ASA) score<3 6. No restriction on gender or race; Informed consent has been signed by patient or entrusted agent; Exclusion Criteria: 1. Previous history of gastric ulcer or gastric perforation; 2. Previous operation history at upper abdominal, except laparoscopic cholecystectomy; 3. Emergency operation caused by obstruction, perforation,and acute hemorrhage; 4. The patient can not tolerate the surgical treatment which caused by other serious concomitant disease, such as severe pulmonary disease, cardiac clinical function below are below level 2, pulmonary infection, moderate or severe chronic obstructive pulmonary disease (COPD), chronic bronchitis 5. Patient has severe mental illness 6. The patient and agent request to withdraw from the clinical study after signing the consent form. |
Country | Name | City | State |
---|---|---|---|
China | West China Hospital, Sichuan University | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
West China Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | General observation of tissue fibrosis, edema and exudation (Intraoperation) | To assess the degree of fibrosis, edema and exudation in tumor tissue and main perigastric lymph node area during the operation. | The 1 day of surgery | |
Secondary | General observation of tissue edema (Intraoperation) | To assess the degree of edema in tumor tissue and main perigastric lymph node area during the operation. | The 1 day of surgery | |
Secondary | General observation of tissue exudation (Intraoperation) | To assess the degree of exudation in tumor tissue and main perigastric lymph node area during the operation. | The 1 day of surgery | |
Secondary | Histopathology evaluation of edema | To assess the degree of edema in tumor tissue and main perigastric lymph node area by pathological section. | The 1 day of surgery | |
Secondary | Histopathology evaluation of tissue fibrosis | To assess the degree of fibrosis in tumor tissue and main perigastric lymph node area by pathological section. | Postoperative 30 days | |
Secondary | Postoperative mortality rate | Calculated by the number of patients with any operative complication as the numerator and the number of patients undergoing surgical treatment. | Postoperative 30 days | |
Secondary | Survival outcome | The 3-year overall survival rate | Postoperative 3 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03982173 -
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
|
Phase 2 | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Not yet recruiting |
NCT04263870 -
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 2 | |
Recruiting |
NCT06362070 -
Comparison of Outcomes of Multiple Platforms for Assisted Robotic - Gastrectomy
|
N/A | |
Active, not recruiting |
NCT05311176 -
A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)
|
Phase 2 | |
Recruiting |
NCT04802876 -
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors
|
Phase 2 |